Suchergebnisse - "Biological Factors"

PubPharm (126)

1

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease

enthalten in: Drugs | 2023

von Gisbert, J. | Chaparro, M.

2

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

enthalten in: Digestive diseases and sciences | 2023

von Eriksson, C. | Söderling, J. | Karlqvist, S. | +7

CommentIn: Dig Dis Sci. 2023 Jul;68(7):2785-2786. - PMID 37024738

3

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent

enthalten in: Journal of Korean medical science | 2022

von Choi, S. | Kim, E. | Kwon, Y. | +4

4

Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma : A single center real life experience

enthalten in: Tuberkuloz ve toraks | 2022

von Yıldız, R. | Demirel, Y. | Mungan, V. | +4

5

Long-term drug survival of secukinumab in real life in the era of novel biologics : a 5-year, retrospective study, including difficult-to-treat areas

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2022

von Sotiriou, E. | Bakirtzi, K. | Vakirlis, E. | +5

6

Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis

enthalten in: Clinical therapeutics | 2022

von Kakiuchi, T. | Yoshiura, M.

7

Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab

enthalten in: Digestive diseases and sciences | 2022

von Costable, N. | Borman, Z. | Ji, J. | +2

8

Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice

enthalten in: Terapevticheskii arkhiv | 2022

von Fomina, D. | Mukhina, O. | Lebedkina, M. | +6

9

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease

enthalten in: European journal of gastroenterology & hepatology | 2021

von Innocenti, T. | Roselli, J. | Lynch, E. | +10

10

Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents : real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Ko, Y. | Paramsothy, S. | Yau, Y. | +1

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]